NovaBay Pharma (NBY) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts NBY Hot Sheet
Price: $1.95 --0%
Financial Fact:
Income (loss) before income taxes: -3.74M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Income (loss) before income taxes: -3.74M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
NovaBay Pharma (NYSE: NBY) reported Q2 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $1.01 million versus the consensus estimate of $610 thousand.
For earnings history and earnings-related data on NovaBay Pharma (NBY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- Socket Mobile (SCKT) Reports Q3 Loss of $0.09
- eHealth (EHTH) Misses Q3 EPS by 45c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
